Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gallium (68Ga) relitegatide brexetan
- Development stage
- Unknown
- Lead developer
- Radiopharm Theranostics, Ltd
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Positron Emitters → Radiopharmaceuticals, Peptides
- Administration
- Intravenous
01
Overview
Gallium (68Ga) relitegatide brexetan (also known as 68Ga-Trivehexin or RAD301) is an investigational, peptide-based diagnostic radiopharmaceutical designed for positron emission tomography (PET) imaging. It consists of the cyclic nonapeptide relitegatide, which selectively targets the cell-surface receptor αvβ6-integrin (an epithelial-specific integrin overexpressed in various cancers and fibrotic tissues), conjugated to the chelator brexetan and radiolabeled with the positron-emitting isotope gallium-68 (68Ga). Originally developed by TRIMT (which was acquired by ABX in 2026) and licensed to Radiopharm Theranostics, the tracer is being clinically evaluated for the detection, staging, and monitoring of pancreatic ductal adenocarcinoma (PDAC), non-small cell lung cancer (NSCLC), head and neck squamous cell carcinoma (HNSCC), and pulmonary fibrosis.
- Brand names
- 68Ga-TrivehexinGa-TrivehexinGa68-TrivehexinGa-68-TrivehexinGa 68-TrivehexinTrivehexin
- Other names
- gallium (68Ga) relitegatide brexetangallium Ga 68 relitegatide brexetangallium Ga-68 relitegatide brexetanrelitegatide brexetan
02
Targets
αVβ6 (Integrin αVβ6)
Beyond the preview
Go deeper on gallium (68Ga) relitegatide brexetan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gallium (68Ga) relitegatide brexetan.